Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Ionis Pharmaceuticals, Inc. ( IONS ) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 7:45 AM EDT Company Participants Brett Monia - Founder, CEO & Director Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Morgan Stanley, Research Division Good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Ulz, one of the biotech analysts, and it's my pleasure to introduce Brett Monia, CEO of Ionis Pharmaceuticals. Just a reminder, the format for today is a fireside chat. But before we start, I just need to read a quick disclosure. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative. And with that, I'll hand it over to Brett. Thanks for joining us. And maybe you can start with a couple of introductory comments before we hop in queue. Brett Monia Founder, CEO & Director Thanks, Mike. Good morning, everybody. It's great to be here, Mike. Thanks for the invite. So as expected and not surprising with the pipeline is deep and rich as ours, we were expecting a highly eventful year for Ionis, and that's exactly where we are with a lot more to come in the remaining months of the year. We're on track this year to push 3 breakthrough medicines across the finish line through the FDA, 3 drug approvals. We already have 2 severe hypertriglyceridemia breakthrough medicine, Tryngolza, was approved few days early in June. And just last week, we had the approval of our first wholly owned neurology medicine, Zanvastro, for Alexander disease, the first disease-modifying treatment ever approved by the FDA. And we're expecting a third FDA approval in October with our partner, GSK, for chronic